Long-term Evaluation of Three Multiple-Case Waldenström Macroglobulinemia Families
Purpose: Because the clinical significance of immunoglobulin abnormalities reported in relatives of familial Waldenström macroglobulinemia (WM) patients is unknown, we initiated a follow-up study of three WM families originally evaluated 27 years previously. Experimental Design: Of 29 eligible first...
Gespeichert in:
Veröffentlicht in: | Clinical cancer research 2007-09, Vol.13 (17), p.5063-5069 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose: Because the clinical significance of immunoglobulin abnormalities reported in relatives of familial Waldenström macroglobulinemia
(WM) patients is unknown, we initiated a follow-up study of three WM families originally evaluated 27 years previously.
Experimental Design: Of 29 eligible first-degree relatives of WM patients, 27 (93%) had originally participated in clinical and electrophoretic
evaluations. We re-contacted all participants for prospective follow-up electrophoretic analysis and other studies.
Results: Initially, five relatives had IgM monoclonal gammopathy (IgM MG), and four had IgM polyclonal gammopathy (PG). Twenty-two
relatives (81%) were re-evaluated. Median follow-up was 17 years (range, 7-27). At re-contact, all IgM MG persisted or progressed,
including three that evolved to WM. Among the four with PG, two new IgM MG cases developed. Overall, seven relatives (26%)
had IgM MG, and five (18%) had IgM PG.
Conclusions: Although based on small numbers, this study provides the longest comprehensive follow-up of WM families to date. IgM MG seems
to be a phenotypic marker of WM susceptibility in some families and may have a high risk of progression to WM. IgM PG may
also be important in WM families. These observations require validation in larger studies and, if confirmed, may be used to
identify a cohort (relatives with IgM MG) for future prevention strategies. |
---|---|
ISSN: | 1078-0432 1557-3265 |
DOI: | 10.1158/1078-0432.CCR-07-0299 |